About Us

Home ... About Us ... Our People ... Board of Directors

Board of directors

Barry Price, PhD Executive Chairman
Dr Price joined Summit as Non-Executive Chairman in September 2006 and appointed Executive Chairman in 2010. Dr Price brings to the Company a wealth of industry and board-level expertise in the pharmaceutical and life sciences industries. Previously, he spent over 25 years with the Glaxo Group of companies and held several executive positions including Managing Director of Glaxochem Ltd. Dr Price was a Non-Executive Director of Shire plc and during his 14 years with the company, he was involved in Shire developing into one of the UK’s largest life science companies. Dr Price is currently Chairman of Antisoma plc and has previously held directorships at Chiroscience plc, Celltech Group plc, Pharmagene plc and BioWisdom Ltd.

Richard Storer, DPhil Chief Scientific Officer
Dr Storer was appointed to the Board of Directors as Chief Scientific Officer in May 2006. He career has spanned over 30 years within the pharmaceutical industry and has overseen the progression of several discovery programmes into clinical development. Several of these were subsequently launched to market including the blockbuster products Epivir and Relenza. His formative years were spent at GlaxoWellcome before moving to BioChem Pharma Inc. (now part of Shire plc) as Senior Director of Chemistry prior to joining Idenix Pharmaceuticals as Senior Vice President of Chemistry. In 1996, Dr Storer received the Canadian Prix Galien for the discovery of 3TC (Epivir) and he is a Fellow of the Royal Society of Chemistry.

Professor Stephen Davies Non–executive Director
Professor Davies co-founded Summit in January 2003. He was Chairman of Summit until September 2006 and guided the Company through a successful flotation and the formative years of the Company’s development. In 1992, Prof. Davies founded the spin-out companies Oxford Asymmetry and Oxford Diversity which later combined for the IPO of Oxford Asymmetry International. This subsequently merged in 2000 with Evotec for £316 million. He has been professor at Oxford University for over 20 years and was elected to the Waynflete Chair of Chemistry in 2006, one of the most prestigious academic posts in UK science. In addition, Prof. Davies has received numerous awards for his contribution to organic chemistry. Prof. Davies currently holds directorships with Isis Innovations Ltd and Sci-ink Ltd.

Andrew Richards, PhD Non–executive Director
Dr Richards was appointed to the Summit Board as a Non-Executive Director in March 2007 following the acquisition of DanioLabs Ltd. As a biotechnology entrepreneur, he founded Chiroscience in 1992 and was an Executive Director until its merger with Celltech in 1999. Currently Dr Richards is a Director at Vectura plc, Theradeas Ltd, Cancer Research Technology Ltd (the commercial arm of CR-UK), Babraham Bioscience Technology Ltd, Arecor Ltd and is Chairman of Novacta Biosystems Ltd, Ixico Ltd and Altacor Ltd. He is also a founding member of the Cambridge Angels and a member of the council of the BBSRC. Dr Richards is a Cambridge graduate with a PhD in enzyme chemistry.

George Elliott, CA Non–executive Director
Mr Elliott joined the Summit Board of Directors in April 2007. From 2000 to 2007, Mr Elliott served as Chief Financial Officer and Finance Director of Wolfson Microelectronics plc and during his time oversaw the company gain entry into the FTSE 250 index. Previously he was Business Development Director at McQueen International Ltd (now SYKES), where he was responsible for strategic sales and marketing. Mr Elliott is currently Non-Executive Chairman of Craneware plc and Corsair Components Inc. and holds Non-Executive Directorships with Easy Date Holdings and Scotcloth Ltd. Mr Elliott, formerly a partner of Grant Thornton, is a Chartered Accountant and has a degree in Accountancy and Finance from Heriot-Watt University.